Tag Archives: AIMT
Analysts Offer Insights on Healthcare Companies: Aimmune Therapeutics (NASDAQ: AIMT) and Ligand Pharma (NASDAQ: LGND)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aimmune Therapeutics (AIMT – Research Report) and Ligand Pharma (LGND – Research Report) with bullish sentiments. Aimmune Therapeutics (AIMT) In a report
Credit Suisse Sticks to Its Hold Rating for Aimmune Therapeutics (AIMT)
Credit Suisse analyst Evan Seigerman maintained a Hold rating on Aimmune Therapeutics (AIMT – Research Report) today and set a price target of $15.00. The company’s shares closed last Wednesday at $13.83, close to its 52-week low of $10.09. According
Aimmune Therapeutics (AIMT) Receives a Hold from H.C. Wainwright
H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Aimmune Therapeutics (AIMT – Research Report) today and set a price target of $15.00. The company’s shares closed last Tuesday at $16.86. According to TipRanks.com, Fein is a 5-star analyst
Aimmune Therapeutics (AIMT) Gets a Hold Rating from H.C. Wainwright
H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Aimmune Therapeutics (AIMT – Research Report) today and set a price target of $30.00. The company’s shares closed last Monday at $24.43. According to TipRanks.com, Fein is a 5-star analyst
Aimmune Therapeutics (AIMT) Receives a Buy from Wedbush
Wedbush analyst Liana Moussatos reiterated a Buy rating on Aimmune Therapeutics (AIMT – Research Report) today and set a price target of $74.00. The company’s shares closed last Monday at $25.65. According to TipRanks.com, Moussatos ‘ ranking currently consits of
Analysts Are Bullish on Top Healthcare Stocks: Aimmune Therapeutics (AIMT), Alnylam Pharma (ALNY)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Aimmune Therapeutics (AIMT – Research Report), Alnylam Pharma (ALNY – Research Report) and Bluebird Bio (BLUE – Research Report) with bullish sentiments.
